West Deptford, N.J. – 1st October, 2015 – Johnson Matthey (LSE: JMAT), a leading provider of pharmaceutical services, active pharmaceutical ingredients (APIs) and catalyst technologies, has acquired the Pharmorphix® solid form research business from Sigma-Aldrich. This acquisition brings world-leading material science capabilities to Johnson Matthey’s expanding European API and clinical supply services.
Pharmorphix is an established provider of solid form services, including polymorph studies, salt selection, co-crystallization, chiral separations and process scale up that are critical to successful drug discovery and development. This expertise also has valuable applications for process control, and can enable innovators or generics customers to find new forms for novel or existing pharmaceuticals.
“Pharmorphix serves an important niche area that complements our custom pharma solutions, API life cycle management offerings and existing US-based solid state science capabilities,” said John Fowler, Division Director at Johnson Matthey Fine Chemicals. “The acquisition adds further differentiating technologies to our advanced catalysis and complex chemistry capabilities, building on the expertise that our customers rely on to enable successful drug development and commercialisation.”
The Pharmorphix facilities and staff are located at the Cambridge Science Park, UK, where they will be fully integrated into Johnson Matthey’s expanding Cambridge presence.
About Johnson Matthey’s Fine Chemicals Division
Johnson Matthey’s Fine Chemicals Division provides pharmaceutical customers around the globe with a broad range of services and solutions, including active ingredients, custom development services, catalysts and chiral technologies. To learn more about Johnson Matthey Fine Chemicals, please visit: www.JMFineChemicals.com.
Media enquiries:
Kate Whelan
Notch Communications
kate.whelan@notchcommunications.co.uk
+46(0) 70 238 11 49